Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa-Ethiopia, Kenya, Rwanda, and Tanzania.

East Africa Neglected Tropical Diseases Program medicine safety pharmacovigilance public health program

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
17 02 2021
Historique:
received: 22 01 2021
revised: 10 02 2021
accepted: 12 02 2021
entrez: 6 3 2021
pubmed: 7 3 2021
medline: 24 4 2021
Statut: epublish

Résumé

Monitoring the safety of medicines used in public health programs (PHPs), including the neglected tropical diseases (NTD) program, is a WHO recommendation, and requires a well-established and robust pharmacovigilance system. The objective of this study was to assess the pharmacovigilance systems within the NTD programs in Ethiopia, Kenya, Rwanda, and Tanzania. The East African Community Harmonized Pharmacovigilance Indicators tool for PHPs was used to interview the staff of the national NTD programs. Data on four components, (i) systems, structures, and stakeholder coordination; (ii) data management and signal generation; (iii) risk assessment and evaluation; and (iv) risk management and communication, were collected and analyzed. The NTD programs in the four countries had a strategic master plan, with pharmacovigilance components and mechanisms to disseminate pharmacovigilance information. However, zero individual case safety reports were received in the last 12 months (2017/2018). There was either limited or no collaboration between the NTD programs and their respective national pharmacovigilance centers. None of the NTD programs had a specific budget for pharmacovigilance. The NTD program in all four countries had some safety monitoring elements. However, key elements, such as the reporting of adverse events, collaboration with national pharmacovigilance centers, and budget for pharmacovigilance activity, were limited/missing.

Identifiants

pubmed: 33671293
pii: ijerph18041941
doi: 10.3390/ijerph18041941
pmc: PMC7922898
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Global Health. 2018 Nov 16;14(1):109
pubmed: 30445979
Wkly Epidemiol Rec. 2015 Sep 18;90(38):489-504
pubmed: 26387149
J Clin Med. 2020 May 21;9(5):
pubmed: 32455556
Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130434
pubmed: 24821920
Drug Saf. 2013 Feb;36(2):75-81
pubmed: 23329541
Drug Saf. 2020 Apr;43(4):339-350
pubmed: 31919794
Public Health. 2012 Mar;126(3):233-236
pubmed: 22325616
Trop Med Health. 2014 Jun;42(2 Suppl):21-4
pubmed: 25425947
Lancet Glob Health. 2018 Oct;6(10):e1054-e1055
pubmed: 30223977
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3319
pubmed: 25412180
BMC Public Health. 2017 May 22;17(1):484
pubmed: 28532397
PLoS Negl Trop Dis. 2018 Nov 21;12(11):e0006929
pubmed: 30462639
PLoS Negl Trop Dis. 2009 Aug 25;3(8):e412
pubmed: 19707588
Pathogens. 2020 Nov 06;9(11):
pubmed: 33172114
Infect Dis Poverty. 2017 Nov 20;6(1):158
pubmed: 29151362
Clin Ther. 2014 Mar 1;36(3):421-4
pubmed: 24612943
Pathogens. 2020 Dec 21;9(12):
pubmed: 33371488

Auteurs

Abbie Barry (A)

Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.

Sten Olsson (S)

Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.

Christabel Khaemba (C)

Pharmacy and Poisons Board, Kenya Lenana Road, P.O. Box 27663-00506 Nairobi, Kenya.

Joseph Kabatende (J)

Rwanda Food and Drugs Authority, Nyarutarama Plaza, KG 9 Avenue Kigali, Rwanda.

Tigist Dires (T)

Ethiopian Food and Drug Authority, Africa Avenue, Kirkos Sub City, P.O. Box 5681 Addis Ababa, Ethiopia.

Adam Fimbo (A)

Tanzania Medicines and Medical Devices Authority, Off Mandela Road, Mabibo, P.O. Box 77150 Dar Es Salaam, Tanzania.

Omary Minzi (O)

Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, Muhimbili University of Health and Allied Sciences, P. O. Box 65013 Dar es Salaam, Tanzania.

Emile Bienvenu (E)

College of Medicine and Health Sciences, University of Rwanda, KK 737 Kigali, Rwanda.

Eyasu Makonnen (E)

Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, P.O. Box 9086 Addis Ababa, Ethiopia.
Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT Africa), College of Health Sciences, Addis Ababa University, P.O. Box 9086 Addis Ababa, Ethiopia.

Appolinary Kamuhabwa (A)

Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, Muhimbili University of Health and Allied Sciences, P. O. Box 65013 Dar es Salaam, Tanzania.

Margaret Oluka (M)

Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, P.O. Box 19676-00202 Nairobi, Kenya.

Anastasia Guantai (A)

Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, P.O. Box 19676-00202 Nairobi, Kenya.

Eugène van Puijenbroek (E)

Pharmacovigilance Centre Lareb, 5237 MH 's-Hertogenbosch, The Netherlands.

Ulf Bergman (U)

Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.

Alex Nkayamba (A)

Tanzania Medicines and Medical Devices Authority, Off Mandela Road, Mabibo, P.O. Box 77150 Dar Es Salaam, Tanzania.

Michael Mugisha (M)

College of Medicine and Health Sciences, University of Rwanda, KK 737 Kigali, Rwanda.

Parthasarathi Gurumurthy (P)

Pharmacovigilance and Clinical Trials, Botswana Medicines Regulatory Authority, P.O. Box 505155 Gaborone, Botswana.

Eleni Aklillu (E)

Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH